Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 57
- 试验地点
- 1
- 主要终点
- Myocardial perfusion determined by CMR
研究概览
简要总结
Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI.
Patients are randomized to receive periinterventional intravenous BQ-123 or placebo.
详细描述
Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. We have previously shown that thrombectomy in ST-elevation myocardial infarction (STEMI) accelerates ST-segment resolution, possibly by preventing distal embolization. Therefore, we analyzed the vasoconstrictor concentration of acute coronary thrombi, and found high concentrations of endothelin (ET) which correlated with the magnitude of ST-segment resolution within one hour of percutaneous coronary intervention (PCI). Furthermore, ET-receptor blockade by tezosentan significantly repressed vasoconstriction in an in-vitro model using porcine coronary artery rings incubated with coronary thrombus homogenates extracted from STEMI patients.
The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI.
Methods: Fifty eligible patients will be randomized to receive periinterventional intravenous BQ-123 or placebo. The primary endpoint of the study will be microvascular function evaluated by cardiac magnetic resonance tomography.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •STEMI patients (defined as: Evidence of ischemic chest pain for >30 minutes within <12 hours and new ST-segment elevation for ≥2 mm in two or more contiguous electrocardiographic leads or in case of a true posterior infarction reciprocal ST-segment depressions in in V1 and V2 >1mm and/or elevated serum creatine phosphokinase or twofold elevation of troponin-T), aged 18 years and above, who undergo primary percutaneous revascularization (PCI) and have confirmed initial TIMI 0 or 1 in the infarct related coronary artery.
排除标准
- •Significant liver disease
- •Thrombolytic therapy
- •History of prior myocardial infarction
- •Current atrial fibrillation
- •History of congestive heart failure
- •History of migraine headache
- •Significant valvular heart disease, primary myocardial disease
- •Cardiogenic shock (sRR <90mmHg or need for inotropic support)
- •Child-bearing potential
- •Inability to read, understand and sign the informed consent
- •Life expectancy <3y
- •Prior organ transplantation
- •Medication with konazoles, ritonavir, rifampicin and sulfonyl-urea derivatives
- •Participation in another clinical study
- •Metal implants contraindicating CMR
研究组 & 干预措施
1
Placebo
干预措施: Placebo (Drug)
2
BQ-123
干预措施: BQ-123 (Drug)
结局指标
主要结局
Myocardial perfusion determined by CMR
时间窗: 3 days
次要结局
- Left ventricular function determined by CMR(3 days/ 6 months (6-months Remodeling-substudy))
- Final infarct size determined by CMR(3 days)
- Plasma NT-BNP(30 days/ 6 months (6-months substudy))
- Enzymatic infarct size (CK levels)(3 days)
- ECG ST-segment resolution(1 hour)
- Markers of inflammation(24 hours/ 30 days)
- Major adverse cardiac events (MACE) (cardiovascular death, re-hospitalization for unstable angina and AMI, hospitalization for worsening heart failure)(30 days)
- Liver function(24hours/ 3 days/ 30 days)
- Event free survival(6 months (6-months substudy))
- Holter ECG(3 days / 30 days (EP-substudy))
研究者
Irene Lang
PI
Medical University of Vienna